We then used a Kaplan–Meier survival model to depict the differences between high and low expression of three markers (CTLA4, OX40L, and CD11c) and their effects on the time to biochemical relapse for prostate cancer patients (Figure 4). The gene discussed is TNFSF4; the disease is prostate carcinoma.